2. Academic Validation
  3. Gö6983 attenuates breast cancer-induced osteolysis by the apoptotic pathway

Gö6983 attenuates breast cancer-induced osteolysis by the apoptotic pathway

  • Cell Biol Int. 2020 Mar;44(3):838-847. doi: 10.1002/cbin.11281.
Zhiwei Luan 1,  Jia Li 2,  Xing Huang 3,  Wenyu Feng 3,  Shiting Ma 3,  Fengyang Song 3,  Zhengyuan Wu 3,  Xiaohan Zhang 1,  Linfeng Wei 3,  Zhenyi Yang 3,  Jun Yao 3
Affiliations

Affiliations

  • 1 Guangxi Collaborative Innovation Center for Biomedicine, Guangxi Medical University, Nanning, China.
  • 2 Departments of Pathology, The First Affliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
  • 3 Departments of Orthopedics, The First Affliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
PMID: 31814221 DOI: 10.1002/cbin.11281
Abstract

Bone metastasis caused by breast Cancer leads to significant complications in treatment, and the resulting osteolysis considerably affects patients' overall survival and quality of life. Gö6983 is a broad spectrum protein kinase C inhibitor. In this study, based on our finding that the Gö6983 inhibits osteolysis, we applied Gö6983 to the MDA-MB-231 breast cancer-induced mouse bone metastasis model. And we found that Gö6983 has a strong inhibitory effect on the tumorigenic model of breast Cancer by promoting the mitochondrial Apoptosis pathway. Our study, therefore, demonstrates that Gö6983 has a potential inhibitory effect on breast cancer-induced osteoclast activation and provides mechanistic insight that may prove useful for designing future treatments.

Keywords

Gö6983; RANKL; osteoclast; protein kinase C.

Figures
Products